• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$0.24 -$0.01 (-2.08%)

Quote as of

AVITA MEDICAL LTD ORD

NASDAQOTH:AVMXF.PK

Avita Medical Initiates US FDA Study of Its ReCell® Spray-On-Skin™ for Reconstructive and Aesthetic Indications

Avita Medical Initiates US FDA Study of Its ReCell® Spray-On-Skin™ for Reconstructive and Aesthetic Indications

Avita Medical Granted European Patent Covering Platform Technology

Avita Medical Granted European Patent Covering Platform Technology

Avita Medical Sponsors Inaugural Skin Regeneration Symposium

Avita Medical Sponsors Inaugural Skin Regeneration Symposium

Avita Medical Begins Trading Securities in the U.S.

Avita Medical Ltd. Joins OTCQX

Avita Medical Initiates Trading on US OTCQX

Avita Medical Commences Trading on the US OTCQX International Exchange

Avita Medical Commences Trading on the US OTCQX International Exchange

Avita Medical Acquires Intellectual Property from McComb Foundation, Including Core IP Related to ReCell® Spray-On Skin™

Avita Medical Launches ReCell Spray-On-Skin Treatment of Venous Ulcers

Avita Medical Launches ReCell® Spray-On-Skin™ Treatment of Venous Ulcers

Avita Medical Enters into Joint Venture to Expand Sales of ReCell® Spray-On Skin™ Throughout the Middle East and North Africa

Avita Medical Enters into Joint Venture to Expand Sales of ReCell® Spray-On Skin™ Throughout the Middle East and North Africa

Avita Medical Appoints Senior Researcher Dr. Michael Mendicino to Lead and Expand Its Regenerative Medicine R&D Program

Avita Medical Appoints Senior Researcher Dr. Michael Mendicino to Lead and Expand Its Regenerative Medicine R&D Program

Avita Medical Appoints Senior Researcher Dr. Michael Mendicino to Lead and Expand Its Regenerative Medicine R&D Program

Avita Medical Receives FDA Approval to Initiate Study of Its ReCell® Spray-On-Skin™ for Cosmetic Indications

Avita Medical Receives FDA Approval to Initiate Study of Its ReCell® Spray-On-Skin™ for Cosmetic Indications

Wilson HTM Initiates Coverage of Avita Medical

Wilson HTM Initiates Coverage of Avita Medical

Avita Medical Closes Equity Raising AUD$9m

Avita Medical Reports Additional Market Acceptance of its ReCell® Spray-On-Skin™

Avita Medical Begins Commercialization of ReCell® Spray-on-Skin™ in Six Countries in the Arabian Peninsula

Avita Medical Reports Third Quarter- and Nine-Month Financial Results

Avita Medical Reports Third Quarter- and Nine-Month Financial Results

Study Demonstrates That Avita Medical’s ReCell® Spray-On Skin™ in Combination with a Biological Wound Dressing Has “a Number of Benefits Compared to Standard Skin-Grafting Techniques”

Study Demonstrates That Avita Medical's ReCell® Spray-On SkinT "Has Potentially Broad Application To The Healing Of Acute And Chronic Wounds"

Study Demonstrates That Avita Medical’s ReCell® Spray-On Skin™ “Has Potentially Broad Application to the Healing of Acute and Chronic Wounds”

Avita Medical Expands Sales and Marketing Operations in Europe

Australian Market Report of May 31, 2010: Avita Medical (ASX:AVH) Advances Marketing in China and Taiwan